Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Finished Goods (2020 - 2025)

IGC Pharma has reported Finished Goods over the past 6 years, most recently at $212000.0 for Q3 2025.

  • Quarterly Finished Goods fell 47.52% to $212000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $212000.0 through Sep 2025, down 47.52% year-over-year, with the annual reading at $256000.0 for FY2025, 41.95% down from the prior year.
  • Finished Goods was $212000.0 for Q3 2025 at IGC Pharma, down from $271000.0 in the prior quarter.
  • Over five years, Finished Goods peaked at $1.0 million in Q3 2021 and troughed at $212000.0 in Q3 2025.
  • The 5-year median for Finished Goods is $533000.0 (2023), against an average of $591631.6.
  • Year-over-year, Finished Goods soared 222.95% in 2021 and then tumbled 47.52% in 2025.
  • A 5-year view of Finished Goods shows it stood at $889000.0 in 2021, then dropped by 20.58% to $706000.0 in 2022, then dropped by 27.62% to $511000.0 in 2023, then fell by 28.77% to $364000.0 in 2024, then plummeted by 41.76% to $212000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Finished Goods are $212000.0 (Q3 2025), $271000.0 (Q2 2025), and $256000.0 (Q1 2025).